Pharmaron Beijing Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Pharmaron Beijing has been growing earnings at an average annual rate of 17.8%, while the Life Sciences industry saw earnings growing at 20.1% annually. Revenues have been growing at an average rate of 24.3% per year. Pharmaron Beijing's return on equity is 13%, and it has net margins of 16%.
Belangrijke informatie
17.8%
Groei van de winst
16.4%
Groei van de winst per aandeel
Life Sciences Groei van de industrie | 41.4% |
Inkomstengroei | 24.3% |
Rendement op eigen vermogen | 13.0% |
Nettomarge | 16.0% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Pharmaron Beijing geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 11,795 | 1,884 | 1,888 | 484 |
30 Jun 24 | 11,502 | 1,928 | 1,895 | 474 |
31 Mar 24 | 11,485 | 1,483 | 1,883 | 465 |
31 Dec 23 | 11,538 | 1,601 | 1,895 | 448 |
30 Sep 23 | 11,424 | 1,553 | 1,966 | 402 |
30 Jun 23 | 11,272 | 1,575 | 1,950 | 381 |
31 Mar 23 | 10,887 | 1,474 | 1,887 | 320 |
01 Jan 23 | 10,266 | 1,375 | 1,749 | 282 |
30 Sep 22 | 9,545 | 1,582 | 1,533 | 219 |
30 Jun 22 | 8,793 | 1,682 | 1,355 | 171 |
31 Mar 22 | 8,057 | 1,664 | 1,147 | 162 |
31 Dec 21 | 7,444 | 1,661 | 1,033 | 152 |
30 Sep 21 | 6,849 | 1,423 | 954 | 146 |
30 Jun 21 | 6,226 | 1,258 | 856 | 127 |
31 Mar 21 | 5,664 | 1,317 | 820 | 113 |
31 Dec 20 | 5,134 | 1,172 | 761 | 105 |
30 Sep 20 | 4,717 | 1,008 | 691 | 89 |
30 Jun 20 | 4,314 | 865 | 636 | 79 |
31 Mar 20 | 3,953 | 594 | 605 | 75 |
31 Dec 19 | 3,757 | 547 | 574 | 63 |
30 Sep 19 | 3,499 | 437 | 547 | 51 |
30 Jun 19 | 3,274 | 378 | 525 | 44 |
31 Mar 19 | 3,089 | 346 | 498 | 34 |
31 Dec 18 | 2,908 | 333 | 461 | 32 |
30 Sep 18 | 2,713 | 300 | 686 | 46 |
31 Dec 17 | 2,294 | 231 | 374 | 23 |
31 Dec 16 | 1,634 | 177 | 280 | 0 |
31 Dec 15 | 1,128 | 74 | 221 | 0 |
31 Dec 14 | 790 | 21 | 155 | 0 |
Kwaliteitswinsten: 3759 has high quality earnings.
Groeiende winstmarge: 3759's current net profit margins (16%) are higher than last year (13.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 3759's earnings have grown by 17.8% per year over the past 5 years.
Versnelling van de groei: 3759's earnings growth over the past year (21.3%) exceeds its 5-year average (17.8% per year).
Winst versus industrie: 3759 earnings growth over the past year (21.3%) exceeded the Life Sciences industry -7%.
Rendement op eigen vermogen
Hoge ROE: 3759's Return on Equity (13%) is considered low.